SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ — Lunit today announced a Reference Site Agreement with RadLink, a subsidiary of the Fullerton Health Group, Singapore’s leading private diagnostic and molecular imaging service provider.
As a leading medical AI company, Lunit provides AI software that detects and analyzes radiology images. The most mature products–Lunit INSIGHT CXR and Lunit INSIGHT MMG–provide AI-powered detection of lesions that are suspicious of chest abnormalities and breast cancer with 96-99% accuracy and visualize the location of the findings.
Dr. Chee Way Eng, Medical Director and Managing Director of RadLink Diagnostic Imaging, and Dr. Niketa Chotai, Consultant of RadLink Diagnostic and Head of Breast Imaging, will also participate as Lunit’s Ambassadors, to perform further analysis and case studies.
Dr. Eng commented, “Having used Lunit’s AI technology, we expect Lunit INSIGHT products to improve the overall productivity and accuracy of the radiologists.”
“I am super excited to use the recently added Lunit INSIGHT MMG at RadLink,” said Dr. Chotai. “The initial results using Lunit INSIGHT MMG at Radlink look impressive. It feels like having another expert to evaluate the images. I look forward to serving our patients better.”